SUPG receives briefing coverage of the bus week article.
01:08 SUPG SuperGen profiled in Inside Wall Street - BusinessWeek Online (4.61 )
BusinessWeek Online reports sales of SuperGen's (SUPG) Dacogen could hit $120 mln in 2007, according to Rodman & Renshaw, who rates the stock a buy, with a 12-month target of 24. SuperGen's own estimate is a more modest $100 mln. Its royalties from MGI Pharma (MOGN), which ownsn 9% of SUPG, will grow as sales expand, so Piros expects MGI to buy SuperGen at some point. Vinny Jindal of ThinkEquity Partners also rates SuperGen a buy, but with a much lower 12-month target of 8. He expects to see an uptick in Dacogen sales in the first quarter.